Keyword: Yale Cancer Center
Yale scientists have combined the gene-editing system CRISPR with gene therapy to help the immune system find tough-to-spot tumor cells.
The mechanism by which PARP inhibitors in BRCA-mutated cancers work could make them applicable to many more cancer types.
BMS is combining Opdivo and cabiralizumab, an anti-CSF-1 antibody, with Apexigen’s lead CD40 activator in an early-phase solid tumor study.
Bristol-Myers Squibb has added Yale Cancer Center to its list of participants in a cancer immunotherapy initiative.
Bristol-Myers Squibb has appointed Thomas Lynch to replace Francis Cuss as CSO.